An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modeling.
BACKGROUND
Chemotherapy-related nausea is experienced by most cancer patients receiving chemotherapy. Although vomiting is managed well with current antiemetics, nausea is difficult to manage and little is understood about its development.


OBJECTIVE
The aim was to determine whether nausea exists as part of a symptom cluster and evaluate the symptom cluster's impact on patients' quality of life, psychological distress, and nutritional status.


METHODS
A prospective observational design over two cycles of chemotherapy was used. Patients completed the Memorial Symptom Assessment Scale, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Therapy-General, and Patient-Generated Subjective Global Assessment before chemotherapy and at the end of the first and second cycles of treatment. Random forest modeling, a state-of-the-art prediction method, was used to analyze the data.


RESULTS
One hundred four patients participated in the study. Nausea was found to be a dynamic experience, changing over time. "Core" symptoms, predictive of the presence of nausea, were identified and included appetite loss, feeling bloated, vomiting, taste changes, and lack of energy. Although nausea alone did have an impact on patient outcomes, the impact was significantly higher in relation to physical and functional quality of life and nutritional status in those patients who had more than two symptoms from the nausea cluster.


CONCLUSIONS
This exploratory study, using an innovative analytical approach, has shown that nausea is a complex symptom affected by the presence and/or severity of other concurrent symptoms (the symptom cluster). The findings have implications for the measurement of nausea and also to target people for interventions to manage nausea and its cluster of symptoms.
School of Nursing, Midwifery & Social Work, University of Manchester, Manchester, United Kingdom. alex.molassiotis@manchester.ac.uk
Alex
A
Molassiotis
Carole
C
Farrell
Kathryn
K
Bourne
Sarah G
SG
Brearley
Mark
M
Pilling
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009752:Nutritional Status; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011788:Quality of Life
D000932:Antiemetics; D000970:Antineoplastic Agents